Sylentis specializes in ocular gene silencing, focusing on innovative therapies to improve and extend vision. The company employs a proprietary software tool called SirFinder™, which is instrumental in identifying specific mRNA sequences within genes. This technology facilitates the design of small interfering RNA (siRNA) compounds that exhibit high silencing efficiency and specificity. By leveraging this advanced algorithm, Sylentis aims to develop RNA interference (RNAi)-based therapies that target the excessive production or malfunction of proteins associated with various ocular diseases, such as dry eye syndrome and macular degeneration.

One of Sylentis' key products, SYL1801, is a chemically modified siRNA currently in Phase II clinical research for treating wet age-related macular degeneration (AMD). This innovative treatment is administered as an eye drop solution, targeting the Nrarp gene to inhibit the synthesis of a protein that plays a crucial role in new blood vessel formation in the retina. By offering a non-invasive delivery method, SYL1801 addresses a significant unmet medical need, as current treatments for AMD typically require invasive intraocular injections. This approach not only aims to enhance patient comfort but also seeks to improve the overall quality of life for individuals suffering from this degenerative condition.

Spain

Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design.

Most advanced product of the company are treatments for glaucoma and dry eye syndrome.

Sylentis

Company Details